Alembic Pharmaceuticals Limited has declared the voting results of its 16th Annual General Meeting (AGM), held on August 5, 2026. Shareholders approved the adoption of audited financial statements for FY26 and dividend declarations with near-unanimous support. However, the special resolution to appoint Sujit Jaysukh Bhayani as an Independent Director recorded significant opposition from public institutional investors, who voted against the proposal at a rate of 34.85%.

The meeting was conducted via Video Conferencing (VC) and Other Audio Visual Means (OAVM). S. Samdani of Samdani Shah & Kabra served as the Scrutinizer, confirming compliance with Section 108 of the Companies Act, 2013, and Rule 20 of the Companies (Management and Administration) Rules, 2014. The filing was submitted under Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Voting Participation

A total of 89,089 shareholders were on record as of July 29, 2026. Seventy-eight shareholders attended the meeting through VC/OAVM, comprising 38 from the promoter group and 40 from the public category. Remote e-voting was facilitated by National Securities Depository Limited (NSDL) from August 2 to August 4, 2026.

Resolution Outcomes

All five resolutions were passed with the requisite majority. The ordinary resolutions regarding financial statements, dividends, director re-appointment, and cost auditor remuneration received overwhelming support, with votes in favor exceeding 99.7% across all categories.

Key Observations

The appointment of Pranav Amin (DIN: 00245099), who retired by rotation, saw minor dissent primarily from public institutions, which voted against at a rate of 1.39%. In contrast, the appointment of Sujit Jaysukh Bhayani (DIN: 01767427) as an Independent Director triggered substantial resistance. While promoters and non-institutional public shareholders supported the move, public institutions voted against it at a rate of 34.85%, resulting in 1,21,41,466 votes against out of 3,48,38,920 polled in that category. Despite this, the resolution passed with an overall support of 93.08%.

Alembic Pharmaceuticals has made the audio recording of its post-results conference call available to investors via its official website. The call took place on August 4, 2026, providing stakeholders with an opportunity to discuss the company’s recent financial performance and strategic outlook. This disclosure follows the company’s earlier intimation to stock exchanges dated July 27, 2026, ensuring transparency and timely access to material information for shareholders and analysts.

The audio file is hosted at the company’s quarterly results section, allowing for easy retrieval by market participants. Manisha Saraf, Company Secretary at Alembic Pharmaceuticals Limited, submitted the hosting details to both the Bombay Stock Exchange (BSE) and the National Stock Exchange of India Ltd. (NSE) on August 4, 2026. The submission serves as a formal record that the mandatory post-result discussion has been conducted and archived as per regulatory requirements.

Disclosure Details

The company communicated the availability of the recording through a formal letter addressed to the Department of Corporate Services at BSE Limited and the Listing Department at NSE. The submission references the initial results announcement made on July 27, 2026, linking the conference call directly to the reported financial outcomes. By hosting the audio online, Alembic Pharmaceuticals ensures that all investors, regardless of their ability to attend the live event, can access the same information.

Regulatory Compliance

This action aligns with listing regulations requiring listed entities to conduct conference calls after announcing financial results and to make recordings available for public access. The prompt submission on the same day as the call demonstrates adherence to compliance timelines. The recording remains accessible at https://alembicpharmaceuticals.com/quarterly-results , serving as a permanent record of the management’s commentary on the quarter’s performance. No additional financial metrics or operational updates were disclosed in this specific filing, which focuses solely on the archival of the conference call audio.